Cybersecurity for smart implants, orthopedic robots, and surgical planning.
Modern orthopedics combines pre-op planning SaMD, intra-op robotics, and increasingly sensor-equipped implants. Each layer needs targeted cybersecurity work.
Smart orthopedic implants and connected surgical instruments are an emerging cyber surface. Sensor data, image-guided navigation, and post-op tracking apps all introduce exposure - and post-op patient apps move the device boundary onto the patient's phone and into your cloud.
Typical clinical uses
Key data flows & integrations
BLE-equipped smart implants need authenticated readouts and privacy-preserving analytics.
Pre-op plans must be integrity-protected from cloud through to robot or guide.
Sensor-equipped orthopedic implants and surgical-navigation platforms are a newer cyber surface. The relevant incident history comes from surgical robotics, image-guided platforms, and post-op tracking apps.
Historical incidents
The 2019 URGENT/11 advisory affected real-time OS components used across orthopedic robots and image-guided navigation systems. FDA directed manufacturers to assess and disclose exposure.
FDA Safety Communication, Oct 2019CISA ICSMA-19-274-01
The Ripple20 (Treck TCP/IP, 2020) advisory affected widely embedded network stacks used across surgical and imaging platforms, including those integrated into orthopedic workflows.
CISA ICSMA-20-168-01
Multiple orthopedic recovery and post-op tracking apps have disclosed PHI handling issues. These define the baseline expectation for any companion app paired with a smart implant or surgical workflow.
Active threat scenarios
Pre-op plans flowing from cloud through to a robot or patient-specific guide must be integrity-protected end-to-end.
Sensor-enabled implant interrogators paired with weak authentication can leak telemetry or accept unauthorized reads.
Post-op recovery apps frequently inherit consumer-app patterns (analytics SDKs, weak storage) inappropriate for clinical use.
Implicit trust in upstream imaging or planning platforms propagates compromise into the OR.
What FDA reviewers cite
Smart orthopedic implants and connected surgical instruments are an emerging cyber surface - sensor data, image guidance, and post-op tracking apps all introduce exposure.
Threat models must cover the entire navigation chain - imaging, planning, intraop tracking, and the implant itself.
Embedded sensors and BLE are a step-change in cyber surface vs. traditional passive implants - documentation has to reflect that.
Recovery-tracking apps move the device boundary onto the patient's phone and into your cloud - now in scope for FDA.
What FDA scrutinizes
Threat models must cover the entire navigation chain - imaging, planning, intraop tracking, and the implant itself.
Embedded sensors and BLE are a step-change in cyber surface vs. traditional passive implants - documentation has to reflect that.
Recovery-tracking apps move the device boundary onto the patient's phone and into your cloud - now in scope for FDA.
Standards & deliverables
Six deliverables FDA and notified bodies expect across MedTech, with the orthopedic / implants-specific wrinkle on each row. Use it as a scoping checklist before you brief vendors or your QA team.
| Deliverable | Status | Cadence | Standard / guidance | Orthopedic / Implants note |
|---|---|---|---|---|
| SBOM + VEX Machine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component. |
Required | Premarket + monthly refresh | FDA Cybersecurity Guidance §V · CISA SBOM minimum elements | SBOM must include sensor firmware, BLE/NFC interrogators, and cloud analytics SDKs. |
| Postmarket monitoring Continuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path. |
Required | Continuous (≤30-day triage) | FD&C Act §524B · FDA Postmarket Cybersecurity Guidance | Postmarket plan must address long-term implant data privacy and retention obligations. |
| Penetration test scope Black/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling. |
Required | Premarket + on material change | AAMI TIR57 · FDA Premarket Cyber Guidance §VI.A.5 | Pen test scope: sensor → interrogator → cloud chain, image-guided navigation, post-op companion app. |
| Threat model STRIDE-per-interface threat model with documented mitigations and residual-risk acceptance. |
Required | Premarket, refreshed each design change | AAMI TIR57 · FDA Premarket Cyber Guidance §V.A | Model the full image-guided-surgery system: imaging, planning, intraop tracking, and the implant itself. |
| Secure update mechanism Signed firmware/software updates with rollback protection, integrity verification, and staged rollout. |
Required | Designed premarket, exercised lifecycle-long | FDA Cyber Guidance §IV · IEC 81001-5-1 | Updates are practical only for off-implant components; document compensating controls for the implant. |
| Coordinated Vulnerability Disclosure Public CVD policy, intake channel, and SLAs for triage, fix, and customer communication. |
Required | Continuous, lifecycle-long | ISO/IEC 29147 + 30111 · Section 524B(b)(2) | CVD must accept reports from surgeons and OR-staff, not only security researchers. |
Machine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component.
Continuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path.
Black/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling.
STRIDE-per-interface threat model with documented mitigations and residual-risk acceptance.
Signed firmware/software updates with rollback protection, integrity verification, and staged rollout.
Public CVD policy, intake channel, and SLAs for triage, fix, and customer communication.
Risk is workflow-dependent. Passive sensors that only telemeter healing data are lower risk; active or therapeutic implants (e.g., closed-loop spinal cord stimulators, smart prostheses with motor control) get full FDA premarket scrutiny equivalent to other Class III implantables. The threat model has to make that distinction explicit and tie it back to the IEC 14971 risk file so reviewers can see why the cyber controls scale with patient harm.
Pre-op plans, patient-specific instrument (PSI) designs, and implant-design files are integrity-protected from cloud planner through to manufacturer and on to the OR. Every consuming endpoint - the mill, the 3D printer, the navigation system, the robot - verifies a signature before it accepts the file. We document the chain of custody, test the upload/download path for tampering and misrouting, and include the controls in the SPDF so a substituted or altered design cannot reach a patient.
Standard SaMD package: web/API penetration testing, BOLA and multi-tenant authorization checks, SBOM with VEX, threat modeling of the export-to-OR boundary, and authorization scoping for surgeons, residents, and reps. We also test the integration with imaging (DICOM/CT/MR) and any AI segmentation modules as distinct trust boundaries with their own supply-chain controls.
Yes. Any connected implant with a long deployed lifetime needs a documented CVD program, public intake (e.g., security.txt, vendor portal), defined acknowledgment and remediation SLAs, and SBOM monitoring against NVD, vendor advisories, and CISA KEV. FDA's 2026 premarket guidance and section 524B both cite this expectation explicitly for connected devices, and reviewers will look for the artifact.
Same playbook as general surgical robotics: scope the OR sub-network, model the console/arm/imaging integrations as a connected system with explicit trust boundaries, exercise vendor remote-service tunnels for MFA/jump-host/session-recording compliance, and run console-to-arm control-path integrity tests on staging hardware only. Findings feed back into the IEC 14971 risk file and the SPDF.
Yes. The design file's integrity from cloud planner to manufacturer to OR is treated as a tamper-evident chain. We document the signing keys, key custody, signature verification points, and rollback / revocation procedures, and we test the upload/download path for tampering, misrouting, and replay. PSI workflows often span multiple vendors, so trust boundaries and contractual security obligations are made explicit in the threat model.
Each imaging interface is enumerated with its protocol (DICOM C-STORE/Q/R, proprietary), authentication mechanism, and parser. We fuzz the DICOM stack and authorization-test multi-modality service classes. Where the imaging device is third-party, we model it as untrusted input regardless of vendor reputation - DICOM toolkits have a long CVE history and reviewers expect explicit memory-safety evidence.
Typical baseline: FDA 2026 final premarket cybersecurity guidance, AAMI SW96 (security risk management), AAMI TIR57, IEC 62304 (software lifecycle, often Class C), ISO 14971 (risk management), and IEC 60601-1 with applicable particulars where electrically-active. For the EU, MDR Annex I §17.2 and MDCG 2019-16 apply, and we map the same artifacts to both regimes to avoid duplicate work.
When the app or tablet is part of the cleared system, it gets the standard mobile premarket package: MASVS-aligned testing, secure storage, TLS pinning, root/jailbreak detection where clinically justified, and authorization checks against the planner and any device APIs. Off-the-shelf tablets used as accessories are addressed through labeling assumptions and the threat model's environmental controls.
A formal postmarket cybersecurity management plan is now required under section 524B: continuous SBOM monitoring across the implant firmware, programmer, and any cloud planner; CVD intake; severity-based SLAs; controlled patching processes through the QMS; and a secure update mechanism design (signed, anti-rollback, atomic, recovery-safe) you can defend in a recall or 522 conversation. We deliver these as part of the package, not as an afterthought.
For a connected implant with a planner, app, and (often) a robot or guided instrumentation, end-to-end premarket cyber work generally runs 10-16 weeks. Threat modeling and SBOM front-load in weeks 1-4, pen testing across implant firmware, app, planner, and any service interfaces runs in weeks 4-12, and the consolidated submission package and postmarket plan close in the final weeks. Clearance-guarantee terms and timeline are confirmed in writing at kickoff.
Implant telemetry, surgical navigation, and SBOM for connected orthopedic systems.
"The timeliness of this project exceeded my expectations - this was not my experience with other vendors. Blue Goat Cyber delivered a thorough, detailed report and complete testing faster than I anticipated, without compromising quality."
Cybersecurity for smart implants, orthopedic robots, and surgical planning.
